Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01628718 · ClinicalTrials.gov registry record · NA
Adaptive Disclosure: A Combat-Specific PTSD Treatment
A NA study, sponsored by Veterans Medical Research Foundation.
- Completed
- Registry status
- NA
- Development phase
- 122
- Enrollment target
NCT01628718: Completed NA study, sponsored by Veterans Medical Research Foundation.
NCT01628718 is a NA study that has completed, run by Veterans Medical Research Foundation. The registered enrollment target is 122 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01628718, a NA study, has completed, sponsored by Veterans Medical Research Foundation.
- COMPLETED
- Registry status
- NA
- Development phase
- 122 participants
- Enrollment target
Study Summary
The primary objective of this randomized controlled non-inferiority trial is to determine whether or not Adaptive Disclosure (AD), a new combat-specific psychotherapy for Post Traumatic Stress Disorder (PTSD), is as least as effective as Cognitive Processing Therapy, cognitive only version (CPT-C), in terms of its impact on deployment-related psychological health problems (specifically PTSD and depression) and functioning.
Primary Outcome
Proportion of patients recovered (meets Reliable Change Index (RCI) threshold and has change of at least 2SD from baseline to post-treatment), improved (meets positive RCI threshold), unchanged (does not meet RCI threshold) or deteriorated (meets negative RCI threshold) based on change in the CAPS-IV.
Interventions
- BEHAVIORAL Adaptive Disclosure (AD)
- BEHAVIORAL Cognitive Processing Therapy, cognitive version only (CPT-C)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 122 participants |
| Start Date | 2013-03 |
| Est. Completion | 2019-07 |
| Phase | NA |
What the finished NCT01628718 record still lists
NCT01628718 is an interventional study that assigns participants to a tested intervention. The registered 122 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 2 interventions - of which Adaptive Disclosure (AD) is the first listed.
NCT01628718 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01628718 about?
NCT01628718 is a clinical study titled "Adaptive Disclosure: A Combat-Specific PTSD Treatment". The primary objective of this randomized controlled non-inferiority trial is to determine whether or not Adaptive Disclosure (AD), a new combat-specific psychotherapy for Post Traumatic Stress Disorder (PTSD), is as least as effective as Cognitive Processing Therapy, cognitive only version (CPT-C), ...
What is the current status of trial NCT01628718?
This trial is currently completed. It is a NA study. The enrollment target is 122 participants. The study started on 2013-03. Estimated completion is 2019-07.
What interventions are being tested in trial NCT01628718?
The interventions under investigation include: Adaptive Disclosure (AD) (BEHAVIORAL), Cognitive Processing Therapy, cognitive version only (CPT-C) (BEHAVIORAL).
Who is sponsoring clinical trial NCT01628718?
This trial is sponsored by Veterans Medical Research Foundation, which has 35 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01628718's enrollment target sits among peer trials
122 762nd of 2000 higher than 1,239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03363373 · 122 participants · Phase 2
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
- NCT03463954 · 122 participants · NA
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
- NCT04503265 · 122 participants · Phase 1
A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies
- NCT04700527 · 122 participants · Phase 1
The Effects of SCFA Supplementation in Subjects Receiving Abdominopelvic RT: A Randomized Controlled Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia